EmboSure | Disruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery

Summary
EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed. The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body. The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee. As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/190167448
Start date: 01-05-2022
End date: 30-11-2024
Total budget - Public funding: 3 555 104,00 Euro - 2 488 572,00 Euro
Cordis data

Original description

EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed. The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body. The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee. As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.

Status

SIGNED

Call topic

HORIZON-EIC-2021-ACCELERATOROPEN-01

Update Date

09-02-2023
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
EU-Programme-Call
Horizon Europe
HORIZON.3 Innovative Europe
HORIZON.3.1 The European Innovation Council (EIC)
HORIZON.3.1.2 The Accelerator
HORIZON-EIC-2021-ACCELERATOROPEN-01 EIC Accelerator Open 2021